

THERAVANCE INC  
Form 8-K  
May 17, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**FORM 8-K**

---

**Current Report Pursuant**  
**to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event Reported): **May 17, 2011**

---

**THERAVANCE, INC.**

(Exact Name of Registrant as Specified in its Charter)

---

**Delaware**

(State or Other Jurisdiction of  
Incorporation)

**000-30319**

(Commission File Number)

**94-3265960**

(I.R.S. Employer Identification Number)

Edgar Filing: THERAVANCE INC - Form 8-K

**901 Gateway Boulevard  
South San Francisco, California 94080  
(650) 808-6000**

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

Today at the American Thoracic Society International Conference in Denver, Colorado, GlaxoSmithKline plc presented a poster presentation on a Phase 2b study: Dose-Related Efficacy and Optimal Once-Daily Dosing Interval of the Long-Acting Beta2 Agonist (LABA), Vilanterol Trifenatate (VI), in Adults with Persistent Asthma. VI is the LABA in RELOVAIR. RELOVAIR is an investigational product being developed under the LABA collaboration between GSK and Theravance, Inc. as a once-daily medicine that combines Fluticasone Furoate, and the LABA VI for the treatment of patients with chronic obstructive pulmonary disease or asthma. The poster presentation is filed as Exhibit 99.1 to this report and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

| <b>Exhibit</b> | <b>Description</b>  |
|----------------|---|
| Exhibit 99.1   | Dose-Related Efficacy and Optimal Once-Daily Dosing Interval of the Long-Acting Beta2 Agonist (LABA), Vilanterol Trifenatate (VI), in Adults with Persistent Asthma |

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**THERAVANCE, INC.**

Date: May 17, 2011

By:

*/s/ Michael W. Aguiar*

**Michael W. Aguiar  
Chief Financial Officer**

**EXHIBIT INDEX**

| <b>Exhibit</b> | <b>Description</b>  |
|----------------|---|
| Exhibit 99.1   | Dose-Related Efficacy and Optimal Once-Daily Dosing Interval of the Long-Acting Beta2 Agonist (LABA), Vilanterol Trifenatate (VI), in Adults with Persistent Asthma |